The immunomodulator dimethyl taconite inhibits several key steps of angiogenesis in cultured endothelial cells

Abstract

Dimethyl itaconate (DMI) is a cell-permeable derivative of itaconate, a known immunomodulator metabolite synthesized from the Krebs cycle intermediate cis-aconitate by the enzyme aconitate dehydrogenase. Although DMI is not metabolized into itaconate intracellularly, immunomodulatory, anti-inflammatory and anti-oxidative effects has been described for this compound. Some of these processes affected by DMI are directly related to angiogenesis; however, nothing has been published yet in this field. The aim of this work is to evaluate the potential effect of DMI in different key steps of the angiogenic process.